Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months

Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months

Abstract Introduction Risankizumab is approved for treating moderate-to-severe psoriasis. This interim analysis at 25 months evaluated the effectiveness of risankizumab compared with other approved biologics (OtherBios) among patients with moderate-to-severe psoriasis in the 37-month VALUE post-mark...

Full description

Saved in:
Bibliographic Details
Main Authors: Diamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, Andrea Szegedi, Paula C. Luna, Charles W. Lynde, Ahmed M. Soliman, Hongwei Wang, Christian Kaufmann, Doug G. Ashley, Tshepiso Madihlaba, Simone Rubant, Kim A. Papp
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-02-01
Series:Dermatology and Therapy
Subjects:
IL 23 inhibitor
Risankizumab
Moderate-to-severe plaque psoriasis
Skin clearance
Quality of life
Real-world evidence
Online Access:https://doi.org/10.1007/s13555-025-01342-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01342-0

Similar Items